Rejeunesse Fine is a leading dermal rejuvenation technology, offering an outstanding solution for fine lines and wrinkles on the face and neck. Manufactured by Newmedic Co., Ltd. in South Korea, this filler combines safety, longevity, and satisfaction in its application, making it a popular choice among cosmetic treatment options.
Key Features:
- Superior Safety: Composed of 100% cross-linked hyaluronic acid of non-animal origin, Rejeunesse Fine ensures minimal risk of allergic reactions and is free from animal-derived substances.
- Innovative Technology: Utilizes UPHEC technology to minimize BDDE residue, reducing potential adverse reactions.
- Comfortable Treatment: The inclusion of Lidocaine makes the injection process virtually painless, enhancing patient comfort during treatment.
Benefits:
- Durability: Offers lasting effects for over 8 months, providing a cost-effective solution for skin rejuvenation.
- Versatility: Suitable for treating a variety of skin concerns, including crow’s feet, forehead lines, and nasolabial folds.
- Natural Results: Designed to correct fine to medium-depth depressions, delivering subtle and natural-looking enhancements.
Applications of Rejeunesse Fine:
- Eye Area: Effectively treats crow’s feet and other fine lines around the eyes.
- Facial Contours: Ideal for defining lip contours and smoothing nasolabial folds.
- Forehead and Glabella: Addresses wrinkles between the eyebrows and across the forehead.
- Neck Rejuvenation: Helps in modeling and rejuvenating the neck and décolleté areas.
Product Details:
- Composition: Contains 24 mg/ml of hyaluronic acid and 0.3% Lidocaine.
- Packaging: Each package includes one 1.1 ml syringe equipped with a 30G needle.
- Storage: Recommended storage is between 2 – 25°C, with a shelf life of 24 months.
Professional Guidelines: Rejeunesse Fine is intended for use by medical professionals. Potential users must consult with a healthcare provider to ensure suitability, especially considering the product’s contraindications.
Reviews
There are no reviews yet.